SIRT3 (sirtuin 3) is a NAD⁺-dependent deacetylase primarily localized in mitochondria, playing a critical role in regulating energy metabolism, oxidative stress response, and mitochondrial homeostasis. As a member of the sirtuin family, SIRT3 modulates the acetylation status of various mitochondrial proteins, influencing pathways such as fatty acid oxidation, the tricarboxylic acid (TCA) cycle, and antioxidant defense systems. Its involvement in aging, metabolic disorders, and age-related diseases has made it a key focus in biomedical research.
SIRT3 antibodies are essential tools for studying the expression, localization, and function of this enzyme in cells and tissues. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and immunoprecipitation (IP) to detect SIRT3 levels or assess post-translational modifications. Specificity and validation are crucial, as cross-reactivity with other sirtuin family members (e.g., SIRT1. SIRT2) may occur depending on the antibody’s epitope. High-quality SIRT3 antibodies are often validated using knockout cell lines or tissues to confirm target specificity.
Research applications of SIRT3 antibodies span cancer, neurodegenerative diseases, cardiovascular disorders, and metabolic syndromes, where mitochondrial dysfunction is implicated. Commercial SIRT3 antibodies vary in host species (e.g., rabbit, mouse), clonality (monoclonal/polyclonal), and reactivity across human, mouse, or rat samples. Proper antibody selection ensures reliable data in exploring SIRT3’s therapeutic potential or mechanistic roles in health and disease.